SCHEMBL2074992

SCHEMBL2074992

CC(C)(C)OC(=O)NNC1CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.51
BTK Q06187 1/20 0.49
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
MAPK1 P28482 1/20 0.44
EPHX1 P07099 1/20 0.42
KDM1A O60341 1/20 0.42
MAOB P27338 1/20 0.42
CTSK P43235 3/20 0.41
APLNR P35414 1/20 0.40
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CTSS P25774 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9638826 0.93 GAA (0.46) GAABTKKMT2AMEN1MAPK1
SCHEMBL20046896 0.93 GAA (0.46) GAABTKKMT2AMEN1MAPK1
SCHEMBL4492849 0.92 BTK (0.58) GAABTKKMT2AMEN1MAPK1
SCHEMBL573789 0.92 GAA (0.61) GAABTKKMT2AMEN1MAPK1
SCHEMBL4861571 0.91 GAA (0.45) GAABTKKMT2AMEN1MAPK1
SCHEMBL6238424 0.91 BTK (0.54) GAABTKKMT2AMEN1MAPK1
SCHEMBL5287930 0.90 GAA (0.64) GAABTKKMT2AMEN1MAPK1
SCHEMBL5283385 0.90 GAA (0.64) GAABTKKMT2AMEN1MAPK1
SCHEMBL1863269 0.90 GAA (0.64) GAABTKKMT2AMEN1MAPK1
SCHEMBL5299387 0.90 GAA (0.64) GAABTKKMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105503647-A Preparation method of cyclopropylhydrazine hydrochloride SUZHOU HIGHFINE BIOTECH CO LTD 2016-04-20 CN disclosed
WO-2013144295-A1 SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS SANDOZ AG (CH) 2013-10-03 WO disclosed
US-7897771-B2 Fused heterocyclic compounds JANSSEN PHARMACEUTICA NV (BE) 2011-03-01 US disclosed
US-20110040088-A1 FUSED HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2011-02-17 US disclosed
US-20090270370-A1 FUSED HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2009-10-29 US disclosed
US-7579470-B2 Fused heterocyclic compounds JANSSEN PHARMACEUTICA NV (BE) 2009-08-25 US disclosed
US-20080103132-A1 FUSED HETEROCYCLIC COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2008-05-01 US disclosed
EP-1905774-A1 Fused heterocyclic compounds as serotonin receptor modulators Janssen Pharmaceutica, N.V. (BE) 2008-04-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040088-A1 FUSED HETEROCYCLIC COMPOUNDS TPH1, HTR3A, HTR3B GAA 3127/4885BTK 3323/4885KMT2A 3501/4885
US-20090270370-A1 FUSED HETEROCYCLIC COMPOUNDS TPH1, HTR3A, HTR3B GAA 3127/4885BTK 3323/4885KMT2A 3501/4885
US-20080103132-A1 FUSED HETEROCYCLIC COMPOUNDS TPH1, HTR3A, HTR3B GAA 3127/4885BTK 3323/4885KMT2A 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.